Clinical trialNCT05929235RecruitingPhase 1Interventional

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

SponsorFlare Therapeutics Inc.Enrollment120Advanced Urothelial CarcinomaOpen LabelOral Drug Administration

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gopa Iyer, MD
Memorial Slone Kettering
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Terry Friedlander, MD
Recruiting
Yale Cancer Center
New Haven, Connecticut, United States
Daniel Petrylak, MD
Recruiting
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, United States
Jaime R Merchan, MD MMSc
Recruiting
the University of Chicago Medicine
Chicago, Illinois, United States
Randy Sweis, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Joaquim Bellmunt, MD, Ph.D.
Recruiting
Mass General Cancer Center
Boston, Massachusetts, United States
Xin Gao, MD
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Matthew Galsky, MD
Recruiting
Memorial Slone Kettering Cancer Center
New York, New York, United States
Gopa Iyer, MD
Recruiting
Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Matthew Milowsky, MD
Recruiting
the Cleveland Clinic Foundation
Cleveland, Ohio, United States
Shilpa Gupta, MD
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Benjamin Garmezy, MD
Recruiting
Houston Methodist Cockrell Center for Advanced Therapeutics
Houston, Texas, United States
Patrick Prath, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

3-(5,7-Difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile →Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Aug 2023
Primary completion: 30 Oct 2027
Completion: 30 Jan 2028
Last update posted: 20 Apr 2026
Registered enrollment: 120
Registry id: NCT05929235

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.